Literature DB >> 9493489

Female hypoactive sexual desire disorder due to androgen deficiency: clinical and psychometric issues.

J K Warnock1, J C Bundren, D W Morris.   

Abstract

Menopause, surgical or naturally occurring, with reduced or deficient ovarian functioning has a major impact on morbidity and mortality in mid to late life. In particular, a growing body of literature is focusing on the role of androgens in maintaining women's health and emotional well-being. Further study is needed in the administration of physiologic levels of testosterone replacement therapy as an adjustment to estrogen replacement. The Sexual Energy Scale was developed to provide an objective means of measuring the change in a patient's subjective experience of vitality/sexual energy with androgen replacement therapy. The scale also provides a clinical indication for androgen replacement dosage adjustment. Advantages in using low doses of methyltestosterone in women with hypoactive sexual desire disorder are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9493489

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  4 in total

Review 1.  Hormonal aspects of sexual dysfunction: the therapeutic use of exogenous androgens in men and women.

Authors:  S N Seidman
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

Review 2.  Psychotropic drug-induced sexual function disorders: diagnosis, incidence and management.

Authors:  D O Clayton; W W Shen
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

Review 3.  Sexual dysfunction in the older woman: an overview of the current understanding and management.

Authors:  Kathleen E Walsh; Jennifer R Berman
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Improvement in sexual functioning in patients with type 2 diabetes and depression treated with bupropion.

Authors:  Gregory S Sayuk; Britt M Gott; Billy D Nix; Patrick J Lustman
Journal:  Diabetes Care       Date:  2011-02       Impact factor: 19.112

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.